Aeglea BioTherapeutics, Inc. (AGLE)
(Delayed Data from NSDQ)
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AGLE 6.96 +0.24(3.57%)
Will AGLE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGLE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGLE
Take the Zacks Approach to Beat the Market: Shopify, Oracle, Uber in Focus
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
AGLE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails